APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psoriatic Arthritis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Psoriatic Arthritis Drugs Market Outlook and Growth Opportunities 2026

20 December 2025195 pages

Choose your research edition.

Industry ResearchPsoriatic Arthritis Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Psoriatic Arthritis Drugs Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Psoriatic Arthritis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psoriatic Arthritis Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Psoriatic Arthritis Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Psoriatic Arthritis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Psoriatic Arthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psoriatic Arthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psoriatic Arthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Psoriatic Arthritis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Psoriatic Arthritis Drugs market include Janssen, Eli-Lilly, Pfizer, Amgen, Abbvie and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Psoriatic Arthritis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psoriatic Arthritis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psoriatic Arthritis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Psoriatic Arthritis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Psoriatic Arthritis Drugs Segment by Company

Janssen

Eli-Lilly

Pfizer

Amgen

Abbvie

Celgene

Psoriatic Arthritis Drugs Segment by Type

PDE4 Inhibitors

TNF Inhibitors

Interleukin Blockers

Other

Psoriatic Arthritis Drugs Segment by Application

Moderate Psoriatic Arthritis

Severe Psoriatic Arthritis

Mild Psoriatic Arthritis

Psoriatic Arthritis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Psoriatic Arthritis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Psoriatic Arthritis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Psoriatic Arthritis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Psoriatic Arthritis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriatic Arthritis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psoriatic Arthritis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriatic Arthritis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Psoriatic Arthritis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psoriatic Arthritis Drugs industry.

Chapter 3: Detailed analysis of Psoriatic Arthritis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Psoriatic Arthritis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Psoriatic Arthritis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Psoriatic Arthritis Drugs Industry Trends Table 2. Psoriatic Arthritis Drugs Industry Drivers Table 3. Psoriatic Arthritis Drugs Industry Opportunities and Challenges Table 4. Psoriatic Arthritis Drugs Industry Restraints Table 5. Global Psoriatic Arthritis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Psoriatic Arthritis Drugs Revenue Share by Company (2021-2026) Table 7. Global Psoriatic Arthritis Drugs Sales Volume by Company (K Tons) & (2021-2026) Table 8. Global Psoriatic Arthritis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Psoriatic Arthritis Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Psoriatic Arthritis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Psoriatic Arthritis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Psoriatic Arthritis Drugs Company, Product Type & Application Table 13. Global Psoriatic Arthritis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Psoriatic Arthritis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PDE4 Inhibitors Table 18. Significant Companies of TNF Inhibitors Table 19. Significant Companies of Interleukin Blockers Table 20. Significant Companies of Other Table 21. Global Psoriatic Arthritis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Tons) Table 22. Global Psoriatic Arthritis Drugs Sales Volume by Type (2021-2026) & (K Tons) Table 23. Global Psoriatic Arthritis Drugs Sales Volume by Type (2027-2032) & (K Tons) Table 24. Global Psoriatic Arthritis Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Psoriatic Arthritis Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Psoriatic Arthritis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Psoriatic Arthritis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Psoriatic Arthritis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Psoriatic Arthritis Drugs Sales Value Share by Type (2021-2026) Table 30. Global Psoriatic Arthritis Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Moderate Psoriatic Arthritis Table 32. Significant Companies of Severe Psoriatic Arthritis Table 33. Significant Companies of Mild Psoriatic Arthritis Table 34. Global Psoriatic Arthritis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Tons) Table 35. Global Psoriatic Arthritis Drugs Sales Volume by Application (2021-2026) & (K Tons) Table 36. Global Psoriatic Arthritis Drugs Sales Volume by Application (2027-2032) & (K Tons) Table 37. Global Psoriatic Arthritis Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Psoriatic Arthritis Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Psoriatic Arthritis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Psoriatic Arthritis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Psoriatic Arthritis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Psoriatic Arthritis Drugs Sales Value Share by Application (2021-2026) Table 43. Global Psoriatic Arthritis Drugs Sales Value Share by Application (2027-2032) Table 44. Global Psoriatic Arthritis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 45. Global Psoriatic Arthritis Drugs Sales by Region (2021-2026) & (K Tons) Table 46. Global Psoriatic Arthritis Drugs Sales Market Share by Region (2021-2026) Table 47. Global Psoriatic Arthritis Drugs Sales by Region (2027-2032) & (K Tons) Table 48. Global Psoriatic Arthritis Drugs Sales Market Share by Region (2027-2032) Table 49. Global Psoriatic Arthritis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Psoriatic Arthritis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Psoriatic Arthritis Drugs Sales Value Share by Region (2021-2026) Table 52. Global Psoriatic Arthritis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Psoriatic Arthritis Drugs Sales Value Share by Region (2027-2032) Table 54. Global Psoriatic Arthritis Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 55. Global Psoriatic Arthritis Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 56. Global Psoriatic Arthritis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Table 57. Global Psoriatic Arthritis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Psoriatic Arthritis Drugs Sales by Country (2021-2026) & (K Tons) Table 59. Global Psoriatic Arthritis Drugs Sales Market Share by Country (2021-2026) Table 60. Global Psoriatic Arthritis Drugs Sales by Country (2027-2032) & (K Tons) Table 61. Global Psoriatic Arthritis Drugs Sales Market Share by Country (2027-2032) Table 62. Global Psoriatic Arthritis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Psoriatic Arthritis Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Psoriatic Arthritis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Psoriatic Arthritis Drugs Sales Value Market Share by Country (2027-2032) Table 66. Janssen Company Information Table 67. Janssen Business Overview Table 68. Janssen Psoriatic Arthritis Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 69. Janssen Psoriatic Arthritis Drugs Product Portfolio Table 70. Janssen Recent Development Table 71. Eli-Lilly Company Information Table 72. Eli-Lilly Business Overview Table 73. Eli-Lilly Psoriatic Arthritis Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Eli-Lilly Psoriatic Arthritis Drugs Product Portfolio Table 75. Eli-Lilly Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer Psoriatic Arthritis Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Pfizer Psoriatic Arthritis Drugs Product Portfolio Table 80. Pfizer Recent Development Table 81. Amgen Company Information Table 82. Amgen Business Overview Table 83. Amgen Psoriatic Arthritis Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Amgen Psoriatic Arthritis Drugs Product Portfolio Table 85. Amgen Recent Development Table 86. Abbvie Company Information Table 87. Abbvie Business Overview Table 88. Abbvie Psoriatic Arthritis Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Abbvie Psoriatic Arthritis Drugs Product Portfolio Table 90. Abbvie Recent Development Table 91. Celgene Company Information Table 92. Celgene Business Overview Table 93. Celgene Psoriatic Arthritis Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Celgene Psoriatic Arthritis Drugs Product Portfolio Table 95. Celgene Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Psoriatic Arthritis Drugs Distributors List Table 99. Psoriatic Arthritis Drugs Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Psoriatic Arthritis Drugs Product Image Figure 2. Global Psoriatic Arthritis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psoriatic Arthritis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Psoriatic Arthritis Drugs Sales (2021-2032) & (K Tons) Figure 5. Global Psoriatic Arthritis Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Psoriatic Arthritis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PDE4 Inhibitors Image Figure 10. TNF Inhibitors Image Figure 11. Interleukin Blockers Image Figure 12. Other Image Figure 13. Global Psoriatic Arthritis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 14. Global Psoriatic Arthritis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Psoriatic Arthritis Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Psoriatic Arthritis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Psoriatic Arthritis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Psoriatic Arthritis Drugs Sales Value Share by Type (2021-2032) Figure 19. Moderate Psoriatic Arthritis Image Figure 20. Severe Psoriatic Arthritis Image Figure 21. Mild Psoriatic Arthritis Image Figure 22. Global Psoriatic Arthritis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 23. Global Psoriatic Arthritis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Psoriatic Arthritis Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Psoriatic Arthritis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Psoriatic Arthritis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Psoriatic Arthritis Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Psoriatic Arthritis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Figure 29. Global Psoriatic Arthritis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Psoriatic Arthritis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Psoriatic Arthritis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Psoriatic Arthritis Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Psoriatic Arthritis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Psoriatic Arthritis Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Psoriatic Arthritis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Psoriatic Arthritis Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Psoriatic Arthritis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Psoriatic Arthritis Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Psoriatic Arthritis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Psoriatic Arthritis Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Psoriatic Arthritis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Psoriatic Arthritis Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Psoriatic Arthritis Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • PDE4 Inhibitors
  • TNF Inhibitors
  • Interleukin Blockers
  • Other
Applications
  • Moderate Psoriatic Arthritis
  • Severe Psoriatic Arthritis
  • Mild Psoriatic Arthritis
Companies covered
  • Janssen
  • Eli-Lilly
  • Pfizer
  • Amgen
  • Abbvie
  • Celgene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Psoriatic Arthritis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Psoriatic Arthritis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Psoriatic Arthritis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Psoriatic Arthritis Drugs Market Dynamics
  1. 2.1 Psoriatic Arthritis Drugs Industry Trends
  2. 2.2 Psoriatic Arthritis Drugs Industry Drivers
  3. 2.3 Psoriatic Arthritis Drugs Industry Opportunities and Challenges
  4. 2.4 Psoriatic Arthritis Drugs Industry Restraints
3 Psoriatic Arthritis Drugs Market by Company
  1. 3.1 Global Psoriatic Arthritis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Psoriatic Arthritis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Psoriatic Arthritis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Psoriatic Arthritis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Psoriatic Arthritis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Psoriatic Arthritis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Psoriatic Arthritis Drugs Company Product Type and Application
  8. 3.8 Global Psoriatic Arthritis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Psoriatic Arthritis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Psoriatic Arthritis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Psoriatic Arthritis Drugs Market by Type
  1. 4.1 Psoriatic Arthritis Drugs Type Introduction
  2. 4.1.1 PDE4 Inhibitors
  3. 4.1.2 TNF Inhibitors
  4. 4.1.3 Interleukin Blockers
  5. 4.1.4 Other
  6. 4.2 Global Psoriatic Arthritis Drugs Sales Volume by Type
  7. 4.2.1 Global Psoriatic Arthritis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Psoriatic Arthritis Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Psoriatic Arthritis Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Psoriatic Arthritis Drugs Sales Value by Type
  11. 4.3.1 Global Psoriatic Arthritis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Psoriatic Arthritis Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Psoriatic Arthritis Drugs Sales Value Share by Type (2021-2032)
5 Psoriatic Arthritis Drugs Market by Application
  1. 5.1 Psoriatic Arthritis Drugs Application Introduction
  2. 5.1.1 Moderate Psoriatic Arthritis
  3. 5.1.2 Severe Psoriatic Arthritis
  4. 5.1.3 Mild Psoriatic Arthritis
  5. 5.2 Global Psoriatic Arthritis Drugs Sales Volume by Application
  6. 5.2.1 Global Psoriatic Arthritis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Psoriatic Arthritis Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Psoriatic Arthritis Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Psoriatic Arthritis Drugs Sales Value by Application
  10. 5.3.1 Global Psoriatic Arthritis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Psoriatic Arthritis Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Psoriatic Arthritis Drugs Sales Value Share by Application (2021-2032)
6 Psoriatic Arthritis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Psoriatic Arthritis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psoriatic Arthritis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Psoriatic Arthritis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Psoriatic Arthritis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Psoriatic Arthritis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Psoriatic Arthritis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Psoriatic Arthritis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Psoriatic Arthritis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Psoriatic Arthritis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Psoriatic Arthritis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Psoriatic Arthritis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Psoriatic Arthritis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Psoriatic Arthritis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Psoriatic Arthritis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Psoriatic Arthritis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Psoriatic Arthritis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Psoriatic Arthritis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Psoriatic Arthritis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Psoriatic Arthritis Drugs Sales Value Share by Country, 2025 VS 2032
7 Psoriatic Arthritis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Psoriatic Arthritis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Psoriatic Arthritis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Psoriatic Arthritis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Psoriatic Arthritis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Psoriatic Arthritis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Psoriatic Arthritis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Psoriatic Arthritis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Psoriatic Arthritis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Psoriatic Arthritis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Psoriatic Arthritis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Psoriatic Arthritis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen
  2. 8.1.1 Janssen Company Information
  3. 8.1.2 Janssen Business Overview
  4. 8.1.3 Janssen Psoriatic Arthritis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Psoriatic Arthritis Drugs Product Portfolio
  6. 8.1.5 Janssen Recent Developments
  7. 8.2 Eli-Lilly
  8. 8.2.1 Eli-Lilly Company Information
  9. 8.2.2 Eli-Lilly Business Overview
  10. 8.2.3 Eli-Lilly Psoriatic Arthritis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli-Lilly Psoriatic Arthritis Drugs Product Portfolio
  12. 8.2.5 Eli-Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Psoriatic Arthritis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Psoriatic Arthritis Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Psoriatic Arthritis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Psoriatic Arthritis Drugs Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 Abbvie
  26. 8.5.1 Abbvie Company Information
  27. 8.5.2 Abbvie Business Overview
  28. 8.5.3 Abbvie Psoriatic Arthritis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Abbvie Psoriatic Arthritis Drugs Product Portfolio
  30. 8.5.5 Abbvie Recent Developments
  31. 8.6 Celgene
  32. 8.6.1 Celgene Company Information
  33. 8.6.2 Celgene Business Overview
  34. 8.6.3 Celgene Psoriatic Arthritis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Celgene Psoriatic Arthritis Drugs Product Portfolio
  36. 8.6.5 Celgene Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Psoriatic Arthritis Drugs Value Chain Analysis
  2. 9.1.1 Psoriatic Arthritis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Psoriatic Arthritis Drugs Sales Mode & Process
  6. 9.2 Psoriatic Arthritis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Psoriatic Arthritis Drugs Distributors
  9. 9.2.3 Psoriatic Arthritis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst